The a2 Milk Company Limited (ASX:A2M)
Australia · Delayed Price · Currency is AUD 7.87
-0.03 (-0.38%)
Aug 6, 2025, 4:10 PM AEST
Theseus Pharmaceuticals Income Statement
Financials in millions NZD. Fiscal year is July - June.
Millions NZD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2016 - 2020 |
Operating Revenue | 1,755 | 1,673 | 1,591 | 1,444 | 1,205 | 1,731 | Upgrade |
| 1,755 | 1,673 | 1,591 | 1,444 | 1,205 | 1,731 | Upgrade | |
Revenue Growth (YoY) | 8.32% | 5.17% | 10.21% | 19.81% | -30.37% | 33.05% | Upgrade |
Cost of Revenue | 967.22 | 906.69 | 851.93 | 780.22 | 695.32 | 762.12 | Upgrade |
Gross Profit | 787.79 | 766.63 | 739.16 | 663.52 | 509.71 | 968.57 | Upgrade |
Selling, General & Admin | 588.18 | 566.52 | 539.72 | 488.6 | 301.48 | 334.2 | Upgrade |
Other Operating Expenses | -2.18 | -2.13 | -1.78 | -2.49 | 81.81 | 86.66 | Upgrade |
Operating Expenses | 586 | 564.39 | 537.94 | 486.11 | 383.29 | 420.85 | Upgrade |
Operating Income | 201.79 | 202.24 | 201.22 | 177.41 | 126.42 | 547.72 | Upgrade |
Interest Expense | -3.51 | -4.4 | -4.97 | -2.47 | -0.7 | -0.39 | Upgrade |
Interest & Investment Income | 46.31 | 40.4 | 26.73 | 6.57 | 3.99 | 6.13 | Upgrade |
Other Non Operating Income (Expenses) | -0.09 | -0.1 | -0.12 | -0.12 | -0.07 | -0.06 | Upgrade |
EBT Excluding Unusual Items | 244.49 | 238.14 | 222.86 | 181.39 | 129.64 | 553.4 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | -10.38 | - | Upgrade |
Pretax Income | 244.49 | 238.14 | 222.86 | 181.39 | 119.27 | 553.4 | Upgrade |
Income Tax Expense | 85.21 | 84.26 | 78.02 | 66.65 | 38.61 | 165.24 | Upgrade |
Earnings From Continuing Operations | 159.28 | 153.88 | 144.84 | 114.74 | 80.66 | 388.17 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | -2.33 | Upgrade |
Net Income to Company | 159.28 | 153.88 | 144.84 | 114.74 | 80.66 | 385.84 | Upgrade |
Minority Interest in Earnings | 14.76 | 13.7 | 10.8 | 7.88 | - | - | Upgrade |
Net Income | 174.04 | 167.58 | 155.64 | 122.62 | 80.66 | 385.84 | Upgrade |
Net Income to Common | 174.04 | 167.58 | 155.64 | 122.62 | 80.66 | 385.84 | Upgrade |
Net Income Growth | 4.14% | 7.67% | 26.92% | 52.03% | -79.09% | 34.09% | Upgrade |
Shares Outstanding (Basic) | 723 | 723 | 733 | 744 | 742 | 736 | Upgrade |
Shares Outstanding (Diluted) | 728 | 727 | 737 | 744 | 743 | 740 | Upgrade |
Shares Change (YoY) | 0.06% | -1.37% | -0.96% | 0.14% | 0.33% | -0.21% | Upgrade |
EPS (Basic) | 0.24 | 0.23 | 0.21 | 0.16 | 0.11 | 0.52 | Upgrade |
EPS (Diluted) | 0.24 | 0.23 | 0.21 | 0.16 | 0.11 | 0.52 | Upgrade |
EPS Growth | 4.04% | 9.13% | 28.14% | 51.84% | -79.16% | 34.37% | Upgrade |
Free Cash Flow | 265.85 | 238.72 | 101.21 | 198.86 | 83.74 | 421.61 | Upgrade |
Free Cash Flow Per Share | 0.36 | 0.33 | 0.14 | 0.27 | 0.11 | 0.57 | Upgrade |
Gross Margin | 44.89% | 45.81% | 46.46% | 45.96% | 42.30% | 55.96% | Upgrade |
Operating Margin | 11.50% | 12.09% | 12.65% | 12.29% | 10.49% | 31.65% | Upgrade |
Profit Margin | 9.92% | 10.02% | 9.78% | 8.49% | 6.69% | 22.29% | Upgrade |
Free Cash Flow Margin | 15.15% | 14.27% | 6.36% | 13.77% | 6.95% | 24.36% | Upgrade |
EBITDA | 234.77 | 229.14 | 215.01 | 190.98 | 130.01 | 549.76 | Upgrade |
EBITDA Margin | 13.38% | 13.69% | 13.51% | 13.23% | 10.79% | 31.77% | Upgrade |
D&A For EBITDA | 32.99 | 26.9 | 13.79 | 13.57 | 3.58 | 2.04 | Upgrade |
EBIT | 201.79 | 202.24 | 201.22 | 177.41 | 126.42 | 547.72 | Upgrade |
EBIT Margin | 11.50% | 12.09% | 12.65% | 12.29% | 10.49% | 31.65% | Upgrade |
Effective Tax Rate | 34.85% | 35.38% | 35.01% | 36.74% | 32.37% | 29.86% | Upgrade |
Updated Feb 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.